LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions including Parkinson’s disease, obesity and migraine.
Product candidates include:
- LP-003, long-acting Pramlintide, a peptide drug that reduces caloric intake targeting obesity
- LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine
- NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease.
LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand